Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
Status:
Completed
Trial end date:
2020-03-08
Target enrollment:
Participant gender:
Summary
A Phase IIa single arm open-label study to investigate the safety, tolerability, and PK of
F-652 in combination with systemic corticosteroids in subjects who have undergone
Hematopoietic Stem Cell Transplantation (HSCT) and have newly diagnosed grade II-IV lower GI
acute Graft Verses Host Disease (aGVHD). Treatment with F-652 will be once a week for 4
weeks, with post treatment follow up visits on days 28, 56, 180 and 365.